Nurix Therapeutics disclosed that its orally bioavailable BTK degrader bexobrutideg (NX‑5948) achieved an 83 % objective response rate (ORR) in a Phase 1a/1b study of relapsed or refractory chronic lymphocytic leukemia (CLL) patients presented at the 67th American Society of Hematology (ASH) Annual Meeting. The data, presented by Dr. Zulfa Omer, also reported one complete response and a median progression‑free survival of 22.1 months across all dose levels. The 600 mg once‑daily dose, identified as the recommended phase 2 dose, produced the highest ORR and the longest PFS in the randomized Phase 1b cohort, with no dose‑limiting toxicities and a safety profile comparable to the overall study population. While other reports have cited ORR figures of 80.9 % and 84.2 % in similar studies, the 83 % figure reflects the subset of patients evaluated at ASH 2025.
Bexobrutideg’s performance underscores Nurix’s DEL‑AI platform, which accelerates the discovery of protein‑degrading therapeutics. The drug’s ability to target BTK mutations that confer resistance to existing inhibitors positions it as a potential best‑in‑class BTK degrader and a candidate for accelerated approval. The company plans to advance the drug in the pivotal DAYBreak CLL‑201 trial, which could broaden its commercial pipeline and strengthen its competitive standing in the protein‑degradation space.
In its Q3 2025 earnings release, Nurix reported a net loss of $86.4 million ($1.03 per share) compared with a $49.0 million loss ($0.67 per share) in Q3 2024, and revenue of $7.9 million versus $12.6 million in the prior year. The revenue shortfall was driven by the conclusion of a research term with Sanofi, while the increase in R&D expenses reflected accelerated enrollment and preparation for pivotal trials. CEO Arthur T. Sands said the company is “well capitalized to aggressively develop NX‑5948 in multiple indications” and is preparing to initiate pivotal studies in the fourth quarter of 2025.
Investors reacted negatively to the earnings miss, citing the lower revenue and earnings per share figures. The market’s response highlights the sensitivity of investors to short‑term financial performance even as the company reports promising clinical data.
Nurix reported $428.8 million in cash and marketable securities as of August 31 2025 and completed a $250 million equity offering, providing a robust runway to support ongoing and planned clinical development.
Looking forward, the company remains focused on advancing bexobrutideg through pivotal studies, leveraging its DEL‑AI platform to maintain a competitive edge in the BTK degrader market, and capitalizing on its financial resources to sustain pipeline progress.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.